Skip to content
10-K

Annual Report

Apimeds Pharmaceuticals US, Inc. APUS

0001213900-26-051139

← back to feed
Filed
May 4, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Apr 30, 2026 12.58M sh
Shares Diluted FY 2025 · Dec 31, 2025 10.88M sh
Shares Diluted FY 2025 · Dec 31, 2024 7.9M sh
Capex FY 2025 · Dec 31, 2025 $57.33K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$8.93M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$733.53K
Short Term Investments FY 2025 · Dec 31, 2025 $2M
Cash And Equivalents FY 2025 · Dec 31, 2025 $1.64M
Cash And Equivalents FY 2025 · Dec 31, 2024 $3.46K
Stockholders Equity FY 2025 · Dec 31, 2025 $153.35M
Stockholders Equity FY 2025 · Dec 31, 2024 −$1.36M
Stockholders Equity FY 2025 · Dec 31, 2023 $31.87K
Current Liabilities FY 2025 · Dec 31, 2025 $10.71M
Current Liabilities FY 2025 · Dec 31, 2024 $1.02M
Total Liabilities FY 2025 · Dec 31, 2025 $10.84M
Total Liabilities FY 2025 · Dec 31, 2024 $1.37M
Current Assets FY 2025 · Dec 31, 2025 $13.98M
Current Assets FY 2025 · Dec 31, 2024 $13.06K
Total Assets FY 2025 · Dec 31, 2025 $164.18M
Total Assets FY 2025 · Dec 31, 2024 $13.06K
Eps Diluted FY 2025 · Dec 31, 2025 −$0.55
Eps Diluted FY 2025 · Dec 31, 2024 −$0.18
Eps Basic FY 2025 · Dec 31, 2025 −$0.55
Eps Basic FY 2025 · Dec 31, 2024 −$0.18
Sga Expense FY 2025 · Dec 31, 2025 $10.28M
Sga Expense FY 2025 · Dec 31, 2024 $1.28M
Rd Expense FY 2025 · Dec 31, 2025 $1.63M
Net Income FY 2025 · Dec 31, 2025 −$6M
Net Income FY 2025 · Dec 31, 2024 −$1.39M
Operating Income FY 2025 · Dec 31, 2025 −$11.91M
Operating Income FY 2025 · Dec 31, 2024 −$1.28M